Northwest Biotherapeutics, Inc. (OTCQB: NWBO), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors, holder of $11 million of NW Bio convertible senior notes.

With these Notes otherwise due today, as previously disclosed, NW Bio and Whitebox have negotiated a time payment approach tailored to the Company's development schedule with increasing periodic payments over the course of the next 4 months. As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock.

The details of this cooperative arrangement are available in the 8-K filed by the Company this morning, which can be found on NW Bio's website at www.nwbio.com

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.